share_log

B of A Securities Downgrades ProKidney to Neutral, Lowers Price Target to $2

Benzinga ·  Jan 2 09:08

B of A Securities analyst Jason Gerberry downgrades ProKidney (NASDAQ:PROK) from Buy to Neutral and lowers the price target from $8 to $2.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment